{"entity":{"id":"nct07359404","kind":"trial","name":"Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC","aka":[],"tldr":"A phase 2 trial of sacituzumab govitecan and bevacizumab in triple-negative breast cancer, run by YING FAN, now recruiting.","summary":"Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC is a phase 2, interventional study registered as NCT07359404 by YING FAN, with a registry enrolment figure of 60 participants, started 2024-04-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Sacituzumab Govitecan (SG); Bevacizumab. Conditions listed: Advanced Breast Cancer. Triple-negative eligibility wording from the registry: \"Pathologically confirmed recurrent or metastatic Triple-Negative Breast Cancer (TNBC)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07359404","url":"https://clinicaltrials.gov/study/NCT07359404"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-govitecan","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07359404","phase":"2","setting":"A Phase II Clinical Study of Sacituzumab Govitecan Combined With Bevacizumab for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer","sponsor":"YING FAN","participation":[{"nct":"NCT07359404","source":"https://clinicaltrials.gov/study/NCT07359404","fetchedAt":"2026-10-07T16:55:42.201Z","studySha256":"3de36fa297b1ff1ad6584ea82877c4b74b448800cfd8d31a556991e929ffbee5","overallStatus":"ENROLLING_BY_INVITATION","lastUpdatePosted":"2026-01-22","leadSponsor":"YING FAN","collaboratorCount":0,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":60,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-04-01","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07359404/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}